- Home
- CCCC vs KYTX Comparison
CCCC vs KYTX Comparison
Compare CCCC & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- KYTX
- Stock Information
- Founded
- CCCC 2015
- KYTX 2018
- Country
- CCCC United States
- KYTX United States
- Employees
- CCCC N/A
- KYTX N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- KYTX
- Sector
- CCCC Health Care
- KYTX
- Exchange
- CCCC Nasdaq
- KYTX NYSE
- Market Cap
- CCCC 104.4M
- KYTX 92.1M
- IPO Year
- CCCC 2020
- KYTX 2024
- Fundamental
- Price
- CCCC $1.54
- KYTX $3.07
- Analyst Decision
- CCCC Buy
- KYTX Strong Buy
- Analyst Count
- CCCC 3
- KYTX 5
- Target Price
- CCCC $12.00
- KYTX $19.00
- AVG Volume (30 Days)
- CCCC 995.5K
- KYTX 364.6K
- Earning Date
- CCCC 07-31-2025
- KYTX 08-11-2025
- Dividend Yield
- CCCC N/A
- KYTX N/A
- EPS Growth
- CCCC N/A
- KYTX N/A
- EPS
- CCCC N/A
- KYTX N/A
- Revenue
- CCCC $39,783,000.00
- KYTX N/A
- Revenue This Year
- CCCC N/A
- KYTX N/A
- Revenue Next Year
- CCCC N/A
- KYTX N/A
- P/E Ratio
- CCCC N/A
- KYTX N/A
- Revenue Growth
- CCCC 98.56
- KYTX N/A
- 52 Week Low
- CCCC $1.09
- KYTX $1.78
- 52 Week High
- CCCC $7.66
- KYTX $11.40
- Technical
- Relative Strength Index (RSI)
- CCCC 51.48
- KYTX 54.60
- Support Level
- CCCC $1.36
- KYTX $2.86
- Resistance Level
- CCCC $1.63
- KYTX $3.37
- Average True Range (ATR)
- CCCC 0.14
- KYTX 0.34
- MACD
- CCCC -0.00
- KYTX -0.04
- Stochastic Oscillator
- CCCC 42.86
- KYTX 33.04
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.